
Product Data Sheet

Brilliant Violet 605[™] anti-human CD314 (NKG2D)

Catalog # / Size:	2204160 / 100 tests 2204155 / 25 tests	
Clone:	1D11	
Isotype:	Mouse IgG1, κ	Alet 605"
Reactivity:	Human,Non-human primate	initiant Vic
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605 [™] under optimal conditions. The solution is free of unconjugated Brilliant Violet 605 [™] and unconjugated antibody.	CD314 (clone 1011) Brilliant Violet 605 * * * * * *
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).	Hı İyi
Concentration:	Lot-specific	FI



Human peripheral blood lymphocytes were stained with CD8 FITC, and CD314 (clone 1D11) Brilliant Violet 605^{TM} (left) or mouse lgG1, κ Brilliant Violet 605^{TM} isotype control (right).

Applications:

Applications:	Flow Cytometry
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells or 5 μ l per 100 μ l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.
	Brilliant Violet 605 [™] excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify
	This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Application Notes:	The 1D11 antibody blocks MICA binding to T cells, induces redirected lysis, and costimulates T cells activation and proliferation. Additional reported (for the relevant formats) applications include: immunoprecipitation ^{1,2} , blocking of ligand binding, induction of redirected cell lysis, and costimulation of T cells proliferation ²⁻⁷ .
Application References:	1. Vance RE, <i>et al.</i> 1999. <i>J. Exp. Med.</i> 190:1801. 2. Raulet DH. 2003. <i>Nat. Rev. Immunol.</i> 3:781. 3. Lohwasser S, <i>et al.</i> 1999. <i>Eur. J. Immunol.</i> 29:755. 4. Jamieson AM, <i>et al.</i> 2002.

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com **Description:** CD314 is a homodimeric C-type lectin-like protein also known as NKG2D. It is expressed on NK cells, CD8⁺ T cells, γ/δ T cells, and *in vitro* induced LAK cells. Several molecules have been identified as the ligands for NKG2D, including MHC class-I chain-related protein A (MICA), MICB, and UL16-binding proteins (ULBPs). NKG2D has no intrinsic signaling capacity, but attains this by non-covalent association with DAP10 or DAP12 adaptors. In addition to being a primary activation receptor on NK cells, NKG2D is also a costimulatory receptor for TCR-mediated T cell proliferation and cytokine production. The interaction of NKG2D with its ligands plays a role in the immune surveillance against pathogen and tumor cells, and in the pathogenesis of autoimmune diseases.

Antigen	1. Vance RE, <i>et al.</i> 1999. <i>J. Exp. Med.</i> 190:1801.
References:	2. Raulet DH. 2003. Nat. Rev. Immunol. 3:781.
	3. Lohwasser S, et al. 1999. Eur. J. Immunol. 29:755.

4. Jamieson AM, et al. 2002.